parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in neutrophils	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	99 Parkinson's papers of 1,669	0.39
pathways Reactome	3 pathways; mostly lysosome and autophagy	1.00

No case: the score is under the bar. Receipt 3732

receipt 3771: LAMP2 in dopamine neurons, braak

power: full sample +0.24 (p 0.346, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.346, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.47 (p 0.049, n 18). not the mix.
skeptic: leave-one-out range +0.14 to +0.33, sign flips 0; without severely affected donors +0.24 (p 0.346, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LAMP2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3770: LAMP2 in oligodendrocytes, braak

power: full sample +0.24 (p 0.341, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.341, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.21 (p 0.393, n 18). could be the mix.
skeptic: leave-one-out range +0.16 to +0.42, sign flips 0; without severely affected donors +0.24 (p 0.341, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LAMP2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts